A water extract of Mucuna pruriens provides long-term amelioration of parkinsonism with reduced risk for dyskinesias

Parkinsonism and Related Disorders

Volumn 16, Issue 7, 2010, Pages 458-465

  Lieu, Christopher A ^a   Kunselman, Allen R ^a   Manyam, Bala V ^a   Venkiteswaran, Kala ^a   Subramanian, Thyagarajan ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

6 Hydroxydopamine (6 OHDA); Basal ganglia; Complementary and alternative medicine; Movement disorders; Nigrostriatal degeneration

Indexed keywords

ANTIPARKINSON AGENT; BENSERAZIDE; LEVODOPA; MUCUNA PRURIENS EXTRACT; PLANT EXTRACT; UNCLASSIFIED DRUG; WATER; APOMORPHINE; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC DRUG ADMINISTRATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG MEGADOSE; DYSKINESIA; FEMALE; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; OUTCOME ASSESSMENT; PARKINSONISM; PLANT SEED; POWDER; PRIORITY JOURNAL; RAT; RISK REDUCTION; TREATMENT DURATION; ANALYSIS OF VARIANCE; ANIMAL; CHEMICALLY INDUCED; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; DRUG INTERACTION; DYSKINESIA, DRUG-INDUCED; FORELIMB; INNERVATION; METABOLISM; MUCUNA; PARKINSONIAN DISORDERS; PATHOPHYSIOLOGY; PHYTOTHERAPY; PROCEDURES; PSYCHOMOTOR PERFORMANCE; ROTATION; SPRAGUE DAWLEY RAT; TIME; VIBRISSA;

ANALYSIS OF VARIANCE; ANIMALS; ANTIPARKINSON AGENTS; APOMORPHINE; BENSERAZIDE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DYSKINESIA, DRUG-INDUCED; FEMALE; FORELIMB; MUCUNA; OXIDOPAMINE; PARKINSONIAN DISORDERS; PHYTOTHERAPY; PLANT EXTRACTS; PSYCHOMOTOR PERFORMANCE; RATS; RATS, SPRAGUE-DAWLEY; ROTATION; TIME FACTORS; TYROSINE 3-MONOOXYGENASE; VIBRISSAE;

EID: 77954952694     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2010.04.015     Document Type: Article

References (29)

1. Deogaonkar M., Subramanian T. Pathophysiological basis of drug-induced dyskinesias in Parkinson's disease. Brain Res Brain Res Rev 2005, 50:156-168.
2. Stocchi F. The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson's disease. Parkinsonism Relat Disord 2009, 15(Suppl. 1):S9-S15.
3. Manyam B.V., Sanchez-Ramos J.R. Traditional and complementary therapies in Parkinson's disease. Adv Neurol 1999, 80:565-574.
4. Manyam B.V. Paralysis agitans and levodopa in " Ayurveda": ancient Indian medical treatise. Mov Disord 1990, 5:47-48.
5. Vaidya R.A., Aloorkar S.D., Sheth A.R., Pandya S.K. Activity of bromoergocryptine, Mucuna pruriens and L-dopa in the control of hyperprolactinaemia. Neurol India 1978, 26:179-182.
6. Damodaran M., Ramaswamy R. Isolation of l-3:4-dihydroxyphenylalanine from the seeds of Mucuna pruriens. Biochem J 1937, 31:2149-2152.
7. Bell E.A., Janzen D.H. Medical and ecological considerations of L-dopa and 5-HTP in seeds. Nature 1971, 229:136-137.
8. Mahajani S.S., Doshi V.J., Parikh K.M., Manyam B.V. Bioavailability of L-DOPA from HP-200-a formulation of seed powder of Mucuna pruriens (Bak): a pharmacokinetic and pharmacodynamic study. Phytother Res 1996, 10:254-256.
9. Modi K.P., Patel N.M., Goyal R.K. Estimation of L-dopa from Mucuna pruriens LINN and formulations containing M. pruriens by HPTLC method. Chem Pharm Bull (Tokyo) 2008, 56:357-359.
10. Pras N., Woerdenbag H.J., Batterman S., Visser J.F., Van Uden W. Mucuna pruriens: improvement of the biotechnological production of the anti-Parkinson drug L-dopa by plant cell selection. Pharm World Sci 1993, 15:263-268.
11. Vaidya R.A., Sheth A.R., Aloorkar S.D., Rege N.R., Bagadia V.N., Devi P.K., et al. The inhibitory effect of the cowhage plant-Mucuna pruriens-and L-dopa on chlorpromazine-induced hyperprolactinaemia in man. Neurol India 1978, 26:177-178.
12. Kasture S., Pontis S., Pinna A., Schintu N., Spina L., Longoni R., et al. Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens seed extract in rodent model of Parkinson's disease. Neurotox Res 2009, 15:111-122.
13. Hussian G., Manyam B.V. Mucuna pruriens proves more effective than L-DOPA in Parkinson's disease animal model. Phytother Res 1997, 11:419-423.
14. Katzenschlager R., Evans A., Manson A., Patsalos P.N., Ratnaraj N., Watt H., et al. Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study. J Neurol Neurosurg Psychiatry 2004, 75:1672-1677.
15. Subramanian T., Marchionini D., Potter E.M., Cornfeldt M.L. Striatal xenotransplantation of human retinal pigment epithelial cells attached to microcarriers in hemiparkinsonian rats ameliorates behavioral deficits without provoking a host immune response. Cell Transplant 2002, 11:207-214.
16. Olsson M., Nikkhah G., Bentlage C., Bjorklund A. Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J Neurosci 1995, 15:3863-3875.
17. Schallert T. Behavioral tests for preclinical intervention assessment. NeuroRx 2006, 3:497-504.
18. Schallert T., Fleming S.M., Leasure J.L., Tillerson J.L., Bland S.T. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 2000, 39:777-787.
19. Borlongan C.V., Sanberg P.R. Elevated body swing test: a new behavioral parameter for rats with 6-hydroxydopamine-induced hemiparkinsonism. J Neurosci 1995, 15:5372-5378.
20. Warraich S.T., Allbutt H.N., Billing R., Radford J., Coster M.J., Kassiou M., et al. Evaluation of behavioural effects of a selective NMDA NR1A/2B receptor antagonist in the unilateral 6-OHDA lesion rat model. Brain Res Bull 2009, 78:85-90.
21. Steece-Collier K., Collier T.J., Danielson P.D., Kurlan R., Yurek D.M., Sladek J.R. Embryonic mesencephalic grafts increase levodopa-induced forelimb hyperkinesia in parkinsonian rats. Mov Disord 2003, 18:1442-1454.
22. Steece-Collier K., Soderstrom K.E., Collier T.J., Sortwell C.E., Maries-Lad E. Effect of levodopa priming on dopamine neuron transplant efficacy and induction of abnormal involuntary movements in parkinsonian rats. J Comp Neurol 2009, 515:15-30.
23. McLean I.W., Nakane P.K. Periodate-lysine-paraformaldehyde fixative. A new fixation for immunoelectron microscopy. J Histochem Cytochem 1974, 22:1077-1083.
24. Subramanian T., Emerich D.F., Bakay R.A., Hoffman J.M., Goodman M.M., Shoup T.M., et al. Polymer-encapsulated PC-12 cells demonstrate high-affinity uptake of dopamine in vitro and 18F-Dopa uptake and metabolism after intracerebral implantation in nonhuman primates. Cell Transplant 1997, 6:469-477.
25. Manyam B.V., Dhanasekaran M., Hare T.A. Effect of antiparkinson drug HP-200 (Mucuna pruriens) on the central monoaminergic neurotransmitters. Phytother Res 2004, 18:97-101.
26. An alternative medicine treatment for Parkinson's disease: results of a multicenter clinical trial. HP-200 in Parkinson's Disease Study Group. J Altern Complement Med 1995, 1:249-255.
27. Nagashayana N., Sankarankutty P., Nampoothiri M.R., Mohan P.K., Mohanakumar K.P. Association of L-DOPA with recovery following Ayurveda medication in Parkinson's disease. J Neurol Sci 2000, 176:124-127.
28. Vaidya A.B., Rajagopalan T.G., Mankodi N.A., Antarkar D.S., Tathed P.S., Purohit A.V., et al. Treatment of Parkinson's disease with the cowhage plant-Mucuna pruriens Bak. Neurol India 1978, 26:171-176.
29. Goetze O., Nikodem A.B., Wiezcorek J., Banasch M., Przuntek H., Mueller T., et al. Predictors of gastric emptying in Parkinson's disease. Neurogastroenterol Motil 2006, 18:369-375.